Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can amantadine therapy delay the onset of dementia in Parkinson's disease?

Nature Clinical Practice Neurology volume 2, pages 648–649 (2006)Cite this article

boxed-textInzelberg R et al. (2006) Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 21: 1375–1379

Neurologists should consider the reduction of dementia risk as another potential benefit of using amantadine in PD

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Elbaz A et al. (2002) Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55: 25–31

    Article  Google Scholar 

  2. Aarsland D et al. (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60: 387–392

    Article  Google Scholar 

  3. Tariot PN et al. (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317–324

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Co-director of the Movement Disorders Clinic Saskatoon and Director of the Movement Disorders Frozen Brain Studies Laboratory at the University of Saskatchewan, Saskatoon, SK, Canada

    Alex Rajput

Authors
  1. Alex Rajput
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received funding for clinical trials from Allergan, Kyowa Pharmaceutical, Novartis and Teva Pharmaceutical Industries. He has acted as a paid consultant for GlaxoSmithKline, Prestwick Pharmaceuticals and Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajput, A. Can amantadine therapy delay the onset of dementia in Parkinson's disease?. Nat Rev Neurol 2, 648–649 (2006). https://doi.org/10.1038/ncpneuro0322

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0322

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing